Avenue Therapeutics, Inc.

As of August 14, 2025, Avenue Therapeutics, Inc. is rated as risky due to overvaluation and poor financial metrics, including a Price to Book Value of 0.24, an EV to EBITDA ratio of 0.28, and a troubling ROE of -393.59%, alongside a year-to-date stock return of -57.50% compared to the S&P 500's 12.22%.

As of June 11, 2025, the market trend is mildly bearish, supported by daily moving averages and Bollinger Bands, despite some bullish signals from MACD and KST on longer time frames.

As of March 2022, Avenue Therapeutics, Inc.'s management team includes Dr. Lindsay Rosenwald (Executive Chairman), Dr. Lucy Lu (President and CEO), Dr. Jaideep Gogtay, Ms. Garrett Ingram, Mr. Neil Herskowitz, and Dr. Jay Kranzler (all Directors). They oversee the company's strategic direction and operations.

Avenue Therapeutics, Inc. is a pharmaceutical company developing intravenous Tramadol for post-operative pain management. It has a market cap of $0.83 million and reported a net profit loss of $2 million as of March 2025.

As of Jun 18, Avenue Therapeutics, Inc. has a market capitalization of 0.83 million, classifying it as a Micro Cap, with net sales of 0.00 million and a net profit of -13.71 million over the last four quarters. As of December 2024, the company has shareholder's funds of 2.80 million and total assets of 2.67 million.